The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2017

Filed:

Sep. 03, 2013
Applicants:

U.va. Licensing & Ventures Group, Charlottesville, VA (US);

The University of Birmingham, Birmingham, GB;

Inventors:

Donald F. Hunt, Charlottesville, VA (US);

Jeffrey Shabanowitz, Charlottesville, VA (US);

Stacy A. Malaker, Charlottesville, VA (US);

Victor H. Engelhard, Crozet, VA (US);

Angela Zarling, Richmond, VA (US);

Kara L. Cummings, Charlottesville, VA (US);

Rebecca C. Obeng, Charlottesville, VA (US);

Mark Cobbold, Birmingham, GB;

Assignees:

University of Virginia Patent Foundation, Charlottesville, VA (US);

The University of Birmingham, Birmingham, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); A61K 39/00 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); G01N 33/57496 (2013.01); G01N 33/6863 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/57 (2013.01); C07K 2317/31 (2013.01);
Abstract

A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.


Find Patent Forward Citations

Loading…